SCHEMBL24547474

SCHEMBL24547474

N[C@@H](Cc1ccccc1)C(=O)OC[C@H]1O[C@@H](n2ncc(=O)[nH]c2=O)C(O)C1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.54
USP2 O75604 1/20 0.54
POLB P06746 1/20 0.54
KMT2A Q03164 1/20 0.54
LMNA P02545 1/20 0.51
THRB P10828 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HIF1A Q16665 1/20 0.51
HINT1 P49773 1/20 0.42
SLC15A1 P46059 1/20 0.42
GRIA1 P42261 1/20 0.39
GRIA2 P42262 1/20 0.39
GRIA4 P48058 1/20 0.39
GRIK5 Q16478 1/20 0.39
P2RY6 Q15077 3/20 0.38
P2RY2 P41231 2/20 0.38
P2RY4 P51582 1/20 0.38
NT5E P21589 1/20 0.38
MARS1 P56192 2/20 0.38
P2RY12 Q9H244 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24547473 1.00 MEN1 (0.54) MEN1USP2POLBKMT2ALMNA
SCHEMBL24547637 1.00 MEN1 (0.54) MEN1USP2POLBKMT2ALMNA
SCHEMBL27206625 1.00 MEN1 (0.54) MEN1USP2POLBKMT2ALMNA
SCHEMBL26974862 1.00 MEN1 (0.54) MEN1USP2POLBKMT2ALMNA
SCHEMBL24583359 1.00 MEN1 (0.54) MEN1USP2POLBKMT2ALMNA
SCHEMBL27192927 1.00 MEN1 (0.54) MEN1USP2POLBKMT2ALMNA
SCHEMBL24547616 0.82 SMN1; SMN2 (0.55) MEN1USP2POLBKMT2ALMNA
SCHEMBL24584234 0.82 SMN1; SMN2 (0.55) MEN1USP2POLBKMT2ALMNA
SCHEMBL24547568 0.82 SMN1; SMN2 (0.55) MEN1USP2POLBKMT2ALMNA
SCHEMBL24583403 0.81 SMN1; SMN2 (0.59) MEN1USP2POLBKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858956-B2 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections SOUTHERN RESEARCH INSTITUTE (US) 2024-01-02 US disclosed
US-20220204545-A1 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS OREGON HEALTH AND SCIENCE UNIVERSITY 2022-06-30 US disclosed
WO-2022133323-A1 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS SOUTHERN RESEARCH INSTITUTE (US) 2022-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204545-A1 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS MTAP, GALE, TPMT MEN1 531/4885USP2 1180/4885POLB 2443/4885
US-11858956-B2 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections MTAP, GALE, TPMT MEN1 531/4885USP2 1180/4885POLB 2443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.